Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Janssen Pharmaceutica Products, L.P.: A Johnson & Johnson Company
- Janssen Pharmaceutica is a Johnson & Johnson company driven by dedication to product innovation, customer focus and employee and organization excellence. Since 1992, Janssen has been an active member of the Titusville community. As a socially responsible corporate citizen, Janssen is committed to protecting and improving the environment in communities...
- Case studies
Additional Resources
- Janssen Pharmaceutica Products, L.P. (Corporate Profile).
- Janssen at Washington Crossing 1125 Trenton-Harbourton Rd. PO Box 200 Titusville, NJ 08560-0200 Phone: (800) JANSSEN Web: www.janssen.com Janssen Pharmaceutica Products, L.P., is a company driven by a dedication to product innovation, customer focus and employee/organizational excellence. Since its founding in...
- Research articles 2002-11-01
- ALKERMES Inc.(contract with Janssen Pharmaceutica on Risperdal production)(Brief Article)
- ALKERMES Inc. has signed an agreement with Janssen Pharmaceutica to expand Alkermes' manufacturing capacity for the longacting ... ALKERMES Inc. has signed an agreement with Janssen Pharmaceutica to expand Alkermes' manufacturing capacity for the longacting injectable formulation of antipsychotic Risperdal risperdone, which ...
- Research articles 2001-11-05
- Galapagos to supply chemical compound sets to Johnson & Johnson Pharmaceutical Research & Development, Division of Janssen Pharmaceutica NV
- Mechelen, Belgium; 8 March 2007 - Galapagos NV (Euronext & LSE: GLPG) announced today that its service division, BioFocus DPI, has entered into an agreement to supply small molecule compounds for drug discovery to the Johnson & Johnson...
- Research articles 2007-03-08
- GALANTAMINE HYDROBROMIDE.(Janssen Pharmaceutica Products L.P., Reminyl)(Brief Article)
- Janssen Pharmaceutica Products, L.P., a wholly owned subsidiary of Johnson & Johnson, has received FDA approval for Reminyl galantamine hydrobromide for treatment of moderate Alzheimer's disease. Reminyl is derived from the bulbs of daffodils.
- Research articles 2001-03-12
- JANSSEN PHARMACEUTICA PRODUCTS.(receives approval letter for Reminyl)(Brief Article)
- JANSSEN PHARMACEUTICA Products and Shire Pharmaceuticals Group PLC have received an approvable letter from Food and Drug Administration for Reminyl galantamine hydrobromide, used to treat Alzheimer's disease. This follows approval by Switzerland and successful completion of the European mutal recognition program.
- Research articles 2000-08-07
- BASF, Janssen in timber deal. (News in Brief).(Brief Article)
- The plant and material protection division of Janssen Pharmaceutica NV and BASF Corp. have formed an agreement whereby ... The plant and material protection division of Janssen Pharmaceutica NV and BASF Corp. have formed an agreement whereby Janssen may use chlorfenapyr as a pre-construction...
- Research articles 2002-08-05
- Appeals Court Affirms that Eon Labs' Itraconazole Does Not Infringe Janssen's Patent
- LAKE SUCCESS, N.Y. -- Eon Labs, Inc. (Nasdaq: ELAB) announced today that the United States Court of Appeals for the Federal Circuit unanimously affirmed the judgment of the U.S. District Court for the Eastern District of New York that the Company's generic itraconazole product does not infringe Janssen Pharmaceutica N.V....
- Research articles 2005-06-13
- Prescribing errors raise concern at Janssen
- Janssen Pharmaceutica Products LP has launched a campaign for safe medication dispensing of Reminyl, its drug for treating mild to moderate conditions of Alzheimer's disease. Several reports of errors in prescribing have arisen due to confusion between the product and Amaryl, a diabetes drug marketed by Aventis Pharmaceuticals. Administration of...
- Research articles 2004-11-08
- Janssen - Risperdal: "probably" busted!
- A sales representative for Johnson & Johnson's Janssen Pharmaceutica unit testified that he encouraged doctors to prescribe the antipsychotic drug Risperdal for unapproved uses. Matthew D. Thompson, testifying today in a trial over claims by a former co-worker, said that in 2002 he pushed doctors to consider prescribing Risperdal...
- News items 2009-10-29
- Janssen One of Mercer's Drug Leaders
- Janssen Pharmaceutica's name may not be as familiar as that of Bristol-Myers Squibb, even in Mercer County where both make their homes. But the Belgium native's achievements in the pharmaceutical field are quite impressive.
- Research articles 2000-02-01
- Vivus Signs International Marketing Agreement With Janssen
- MENLO PARK, Calif.--BUSINESS WIRE--Jan. 23, 1997--VIVUS, Inc. (NASDAQ:VVUS) today announced that the company has signed an international marketing agreement with Janssen Pharmaceutica International, a subsidiary of Johnson & Johnson. This agreement for MUSE alprostadil, VIVUS treatment for erectile dysfunction, covers China, multiple Pacific Rim countries excluding Japan,...
- Research articles 1997-01-23
- CISAPRIDE.9/vv254/pp14(1)/lCANAM19980729/tCISAPRIDE.
- CISAPRIDE--Janssen Pharmaceutica N.V., a wholly owned subsidiary of Johnson & Johnson, has received exclusive worldwide rights to Sepracor Inc.'s norcisapride, an isomer of Propulsid cisapride, Janssen's treatment for nocturnal heartburn caused CISAPRIDE--Janssen Pharmaceutica N.V., a wholly owned subsidiary of Johnson & Johnson, has received exclusive...
- Research articles 1998-07-27
- Eon Labs Receives Favorable District Court Ruling on Itraconazole Capsules
- LAURELTON, N.Y. -- Eon Labs, Inc. (Nasdaq: ELAB) announced today that the U.S. District Court for the Eastern District of New York granted judgment in favor of Eon Labs ruling that, while the validity of the patent was upheld, the Company's Itraconazole 100mg capsules does not infringe Janssen Pharmaceutica N.V....
- Research articles 2004-07-30
- PHERIN Pharmaceuticals Inc.(Brief Article)
- PHERIN Pharmaceuticals Inc. has signed a development and licensing agreement with Janssen Pharmaceutica NV, a subsidiary of Johnson & Johnson, for proprietary vomeropherin compounds for the ... PHERIN Pharmaceuticals Inc. has signed a development and licensing agreement with Janssen Pharmaceutica NV, a subsidiary of...
- Research articles 1999-07-12
- Snyder Healthcare Services UK Wins Contract From Johnson & Johnson Venture
- BETHESDA, Md.--BUSINESS WIRE--Nov. 30, 1998--Snyder Communications, Inc. (NYSE: SNC) announced today that one of its UK subsidiaries was awarded a pharmaceutical sales detailing contract by Johnson & Johnson (NYSE: JNJ) unit Janssen Pharmaceutica and Eisai Co., Ltd. Under the agreement, Snyder Healthcare Services will support Janssen and Eisai's launch of...
- Research articles 1998-11-30
- Breakthrough Unified Pain Treatment Advances Introduced At Annual Southern Pain Society Meeting
- Business Editors, Health & Medical Writers ORANGE BEACH, Ala.--BW HealthWire--March 6, 2000 Scientific Meeting to Update Professionals On New Developments in Medicine and Treatment Integration The Southern Pain Society's annual scientific meeting, "Advances in a Unified Approach to Pain: From Theory to Practice," co-sponsored by the...
- Research articles 2000-03-06
- FDA revises Lamisil and Sporanox warnings
- The FDA says it is requiring new warning information for Janssen Pharmaceutica's Sporanox itraconazole and Novartis' Lamisil terbinafine HCl tablets. According to the agency, Janssen is adding a new warning to Sporanox's existing black box label on patients' increased risk of developing congestive heart failure and severe liver problems. Lamisil's...
- Research articles 2001-07-01
- Biovail Announces Supply Agreement for Commercialization of Extended-Release Tramadol
- TORONTO -- Biovail Corporation (NYSE:BVF)(TSX:BVF) today announced that a subsidiary, Biovail Laboratories International SRL, has entered into an exclusive supply agreement with Janssen Pharmaceutica NV Janssen, a division of Johnson & Johnson, for the marketing and distribution of Biovail's once-daily, extended-release formulation of tramadol hydrochloride in 86 countries in two...
- Research articles 2008-01-02
- Alkermes Announces Submission of New Drug Application for RISPERDAL® CONSTA® in Japan
- CAMBRIDGE, Mass. -- Alkermes, Inc. (Nasdaq: ALKS) today announced that the Japanese organization of its partner Janssen-Cilag, Janssen Pharmaceutica K.K., submitted a new drug application to the Pharmaceuticals and Medical Devices Agency PMDA for marketing approval in Japan of RISPERDAL([R]) CONSTA([R]) [risperidone long-acting injection], an atypical antipsychotic medication for the...
- Research articles 2006-12-20
- << Previous
- page 1 of 1
- Next >>
Presented by American Express